Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
Conditions
AML, Childhood · Relapse/Recurrence · Refractory AML · Core Binding Factor Acute Myeloid Leukemia · C-KIT Mutation
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
First Affiliated Hospital Of University of Science and Technology of China, Hefei, Anhui, China
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
Guangzhou Women and Children Medical Center, Guangzhou, Guangdong, China
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
Kaifeng Children's Hospital, Kaifeng, Henan, China
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Third Xiangya Hospital of Central South University, Changsha, Hunan, China
XiangYa Hospital Central South University, Changsha, Hunan, China
Children's Hospital of Soochow University, Suzhou, Jiangsu, China
Contact: Principal Investigator (Shaoyan Hu, MD, PhD)Contact: Principal Investigator (Peifang Xiao, MD)Li Gao, MD (Sub-investigator)Jun Lu, MD (Sub-investigator)Jie Li, MD (Sub-investigator)Xuzhou Children's Hospital, Xuzhou, Jiangsu, China
Qilu Hospital of Shandong University, Jinan, Shandong, China
Children's Hospital Of Fudan University, Shanghai, Shanghai Municipality, China
Study leads
Shaoyan Hu, MD, PhD
Principal Investigator
Children 's Hospital of Soochow University